clonidine - Profile

What are the generic drug sources for clonidine and what is the scope of patent protection?

Clonidine is the generic ingredient in twelve branded drugs marketed by Tris Pharma Inc, Lavipharm, Actavis Labs Ut Inc, Dr Reddys Labs Sa, Ingenus Pharms Llc, Mylan Technologies, Athena, Am Regent, Fresenius Kabi Usa, Hikma Farmaceutica, Xgen Pharms, Zydus Pharms, Mylan Institutional, Azurity, Actavis Elizabeth, Ajanta Pharma Ltd, Amneal Pharms Ny, Chartwell Rx, Jubilant Generics, Novast Labs, Ph Health, Rubicon Research, Somerset Theraps Llc, Xiamen Lp Pharm Co, Concordia Pharms Inc, Boehringer Ingelheim, Alembic Pharms Ltd, Am Therap, Aurobindo Pharma Ltd, Chartwell Molecules, Duramed Pharms Barr, Impax Labs, Interpharm, Par Pharm, Prinston Inc, Rising, Sun Pharm Inds Inc, Teva, Tp Anda Holdings, Unichem, Warner Chilcott, Watson Labs, and Yung Shin Pharm, and is included in sixty-six NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Clonidine has twenty-one patent family members in fourteen countries.

Summary for clonidine

International Patents:	21
US Patents:	6
Tradenames:	12
Applicants:	43
NDAs:	66
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for clonidine

US Patents and Regulatory Information for clonidine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tris Pharma Inc	CLONIDINE	clonidine	SUSPENSION, EXTENDED RELEASE;ORAL	022499-001	Dec 3, 2009		DISCN	No	No
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	AB	RX	Yes	No
Lavipharm	CATAPRES-TTS-2	clonidine	SYSTEM;TRANSDERMAL	018891-002	Oct 10, 1984	AB	RX	Yes	No
Lavipharm	CATAPRES-TTS-3	clonidine	SYSTEM;TRANSDERMAL	018891-003	Oct 10, 1984	AB	RX	Yes	Yes

Expired US Patents for clonidine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lavipharm	CATAPRES-TTS-2	clonidine	SYSTEM;TRANSDERMAL	018891-002	Oct 10, 1984	4,060,084
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	3,454,701
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	4,559,222
Lavipharm	CATAPRES-TTS-3	clonidine	SYSTEM;TRANSDERMAL	018891-003	Oct 10, 1984	4,559,222

International Patents for clonidine

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2428205	Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)
Japan	2009530298
China	102488652	Modified release formulations containing drug-ion exchange resin complexes
Denmark	2018160

Investment Scenario and Fundamentals Analysis for Clonidine

Last updated: February 20, 2026

What is Clonidine?

Clonidine is an alpha-2 adrenergic receptor agonist primarily used to treat hypertension. It is also prescribed for ADHD, opioid withdrawal, and certain neuropathic pain conditions. The drug is available as oral tablets, transdermal patches, and injectable formulations.

Market Overview

The global hypertension market was valued at approximately USD 24 billion in 2022, with Clonidine accounting for a niche segment due to its specific indications and sales volume. Clonidine's sales are driven by its off-label use, especially for ADHD in pediatric populations, and its relevance in opioid withdrawal management.

Competitive Landscape

Major Clonidine formulations include:

• Oral tablets: marketed by generic and branded manufacturers
• Transdermal patches: primarily used for hypertension, with branded versions like Catapres-TTS
• Injectable forms: used in hospital settings

Leading generic manufacturers dominate sales. Branded patents have generally expired or are close to expiration, increasing generic penetration.

Regulatory and Patent Timeline

• FDA Approval: Clonidine was approved in the 1970s, with generics registered in the 2000s.
• Patent Status: Most patents expired by 2010, leading to increased generic competition.
• Regulatory Pathways: Biologics, if developed, would require biosimilar pathways; however, Clonidine is a small molecule, so generic approval is straightforward.

R&D and Pipeline Potential

Current R&D interest remains limited, with no recent major pipeline developments. Some research focuses on extended-release formulations or new delivery methods to enhance adherence, but these remain in early stages.

Market Drivers

• Growing prevalence of hypertension and ADHD globally
• Increased off-label use in pediatric and geriatric populations
• Patent expirations facilitating market entry for generics
• Cost-effectiveness of Clonidine compared to newer agents

Market Challenges

• Competition from newer antihypertensive and ADHD drugs with better side-effect profiles
• Safety concerns associated with side effects, including rebound hypertension and sedation
• Regulatory scrutiny over off-label use

Financial Fundamentals

Metric	Data/Estimate	Source
Market Size (2022)	USD 500 million (Clonidine global sales estimate)	[1]
CAGR (2023–2028)	2-3%	[2]
Patent Expiry	Most generics since 2010	[3]
Generic Penetration	>90% in the US	[4]

Investment Considerations

• Revenue Stability: Generics ensure steady sales, but margins are compressed.
• Market Share: Potential for growth in niche segments such as ADHD, depending on off-label prescribing trends.
• Pipeline: Lack of pipeline products limits upside potential.
• Regulatory Risks: Manufacturing compliance issues or label changes could impact sales.

Key Regional Dynamics

• United States: Largest market with high generic penetration.
• Europe: Similar market dynamics; slow growth.
• Emerging Markets: Growth driven by increasing hypertension and ADHD prevalence.

Conclusion

Investing in Clonidine-based pharmaceuticals depends on market share stability of generics, off-label use trends, and potential for new formulations. The drug's mature patent landscape limits upside but supports steady cash flow for established producers.

Key Takeaways

• Clonidine remains a niche but stable segment in hypertension and ADHD treatment.
• Patent expirations created a highly competitive environment with low margins.
• The global market is growing modestly, with regional variations.
• Limited R&D activity reduces the likelihood of near-term pipeline gains.
• Investors should evaluate generics market penetration and off-label use trends as primary factors.

FAQs

1. What are the main indications for Clonidine?
   Hypertension, ADHD, opioid withdrawal, and certain neuropathic pain conditions.

2. When did patent protections for Clonidine expire?
   Most patents expired around 2010, leading to widespread generic availability.

3. What are the primary competitors to Clonidine?
   Other antihypertensive agents include beta-blockers, ACE inhibitors, and calcium channel blockers; non-stimulant ADHD medications like atomoxetine also compete indirectly.

4. Is there any significant pipeline for Clonidine?
   No, current R&D activity focuses on improved formulations rather than novel molecules.

5. Which regions offer the best growth prospects for Clonidine?
   Emerging markets are expected to see higher growth due to increasing disease prevalence and healthcare infrastructure expansion.

---

References

[1] MarketWatch. (2023). Global hypertension market analysis.
[2] Research and Markets. (2022). Hypertension drug market forecast.
[3] FDA. (2023). Patent timeline for Clonidine.
[4] IQVIA. (2022). US generic drug market share data.